Halozyme Therapeutics Inc. HALO

NAS: HALO | ISIN: US40637H1095 27/03/2026

61,63 USD (-2,62%)

(-2,62%) 27/03/2026

Grafiek Halozyme Therapeutics Inc.

Grafiek Halozyme Therapeutics Inc.

1 dag1d -2,62%
1 week1w -1,96%
1 maand1m -11,77%
3 maanden3m -8,97%
6 maanden6m -15,97%
1 jaar1j -3,42%
5 jaar5j 49,99%

Halozyme Therapeutics Inc. in het nieuws

Toon enkel gratis nieuws

12 maart 2026 · Halozyme Appoints David Ramsay as Interim Chief Financial Officer · Persbericht

6 maart 2026 · U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma · Persbericht

25 februari 2026 · Halozyme to Participate in Upcoming Investor Conferences · Persbericht

17 februari 2026 · Halozyme Reports Full Year 2025 Record Revenue Of $1.4 Billion And Reiterates Strong 2026 Financial Guidance · Persbericht

10 februari 2026 · Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results · Persbericht

28 januari 2026 · Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance · Persbericht

20 januari 2026 · Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update · Persbericht

8 januari 2026 · Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE® · Persbericht

5 januari 2026 · Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity · Persbericht

18 december 2025 · U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer · Persbericht

Profiel Halozyme Therapeutics Inc.

Gezondheidstechnologie

Productie van biologische producten

Website: www.halozyme.com

Hoofdzetel: San Diego, California Verenigde Staten

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe